Florian Obereisenbuchner

Dr. Florian Obereisenbuchner

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2025 in Journal of Pediatric Surgery
Verified
Journal Article
Open access
JHJulia Haehl
Julia Haehl
BHBeate Haeberle
Beate Haeberle
Oliver J. MuenstererOliver J. Muensterer
Oliver J. Muensterer
AHAlexandra Hartel
Alexandra Hartel
AFAlexandra Fröba-Pohl
Alexandra Fröba-Pohl
Moritz WildgruberMoritz Wildgruber
Moritz Wildgruber
Rationale and Objectives Bleomycin electrosclerotherapy (BEST) is a promising treatment for slow-flow vascular malformations (SFVMs). Due to limited paediatric data, this study aimed to assess the safety, effectiveness, and patient-reported outcomes of BEST in children with SFVMs. Material and Methods This monocenter cohort study included patients <18 years with symptomatic SFVMs treated by BEST. Patient records were analysed for procedural details and complications. Symptom severity was objectively classified before and after BEST. A treatment-specific, patient-reported questionnaire assessed mobility, aesthetic concerns, swelling, social participation, pain using a visual analogue scale (VAS), and post-procedural skin discoloration. Outcomes were compared between simple and infiltrative lesions. Results Overall, 68 BEST sessions were performed in 45 children. Total complication rate was 10/68 (14.7%), most commonly pes equinus deformities (5/68, 7.4%) after treating SFVMs in calf muscles. Physician-rated overall symptom severity improved significantly (p<0.001). Treatment-specific, patient-reported questionnaire revealed improved mobility in 14/41 (34.1%) and symptom-free patients in 10/41 (24.4%). Outcome in both aesthetic measure and social participation was mostly rated as improved or perfect (33/41, 80.5%; 35/41, 85.4%). Median VAS pain scale improved significantly (2.0 vs. 0.0, p<0.001). Postprocedural swelling occurred in all children, in 26/41 cases (64.4%) persisting for 2-4 weeks. Postprocedural skin discoloration (41/41, 100%) was mostly (25/41, 61.0%) reported to fade over time. No differences between simple and infiltrative lesions were revealed in all outcome parameters. Conclusion BEST is effective for paediatric SFVMs by objective and subjective measures while maintaining low complication rates. Notably, BEST achieves therapeutic success even in infiltrative SFVMs expanding the range of available treatment options.

27 April 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
VVVeronika Vielsmeier
Veronika Vielsmeier
Vanessa F. SchmidtVanessa F. Schmidt
Vanessa F. Schmidt
FOFlorian Obereisenbuchner
Florian Obereisenbuchner
NSNatascha Platz Batista Da Silva
Natascha Platz Batista Da Silva
WWWalter A. Wohlgemuth
Walter A. Wohlgemuth
CSCaroline Seebauer
Caroline Seebauer
Background/Objectives: Bleomycin electrosclerotherapy (BEST), which combines intralesional bleomycin administration with electroporation, enhances drug uptake and has shown efficacy in treating vascular malformations resistant to conventional therapies. While BEST is increasingly used in various anatomical sites, its application in the upper aerodigestive tract remains underexplored. This study evaluates the safety and effectiveness of BEST in managing slow-flow vascular malformations of the oral cavity, tongue, larynx, and hypopharynx. Methods: In this retrospective, multicenter study, 20 patients with symptomatic slow-flow vascular malformations of the upper aerodigestive tract were treated with BEST. Clinical and radiological assessments were used to evaluate the treatment response, categorized as “significantly reduced”, “reduced”, “stable disease”, or “lesion growth”. Postprocedural complications and functional outcomes were systematically recorded. Results: A total of 29 BEST sessions were performed. Lesions of the tongue (n = 8) and combined oral cavity and tongue (n = 6) showed the highest response rates, with significant symptom reduction in five out of eight and five out of six patients, respectively. Among isolated oral cavity lesions (n = 4), one out of four demonstrated a significant reduction. In contrast, laryngeal and hypopharyngeal lesions (n = 2) had limited response, with one case showing partial reduction and the other remaining stable. Severe complications, including bleeding and dyspnea requiring tracheostomy, limited further treatment in these locations. No systemic adverse events, such as pulmonary toxicity, were observed. Conclusions: BEST is effective for treating vascular malformations of the upper aerodigestive tract, particularly in the tongue and oral cavity, but presents significant risks in laryngeal and hypopharyngeal lesions. A multidisciplinary approach is required to optimize treatment protocols for these challenging locations.

13 April 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
FOFlorian Obereisenbuchner
Florian Obereisenbuchner
CSCaroline T. Seebauer
Caroline T. Seebauer
EBElena Borisch
Elena Borisch
DPDaniel Puhr-Westerheide
Daniel Puhr-Westerheide
SDSinan Deniz
Sinan Deniz
VSVanessa F. Schmidt
Vanessa F. Schmidt
Introduction: Recently, Bleomycin-Electrosclerotherapy (BEST) has emerged as a novel alternative in the treatment of slow-flow vascular malformations. Regarding the commonly affected head and neck area, this procedure has to be safe and controllable due to the close anatomical proximity of critical structures. The aim of this study is to evaluate the safety and clinical outcome of BEST for slow-flow vascular malformations of the head and neck region. Methods: Twenty-five patients with symptomatic predominantly superficial SFVMs were treated by 41 BEST sessions between 11/21 and 09/24. Treatments of lesions involving the aerodigestive tract were excluded. Patient records and imaging findings were analyzed with respect to clinical and procedural details. Changes in overall symptom severity were classified into five categories (complete-, marked-, mild-, no response, and progress) based on patients’ reports. Pre- and postprocedural lesion size was determined by measuring the maximum diameter in three orthogonal planes on MRI. Complications and side-effects including skin discoloration were assessed. Results: The most common indications for treatment were swelling in 17/25 patients (68%), followed by pain (7/25, 28%), and functional impairment (7/25, 28%). Patients received 1.6 ± 1.1 BEST sessions with a median bleomycin dose of 5 mg (range 1–15 mg). Complete response at the end of follow-up was observed in 8/25 (32%), strong reduction of symptoms in 14/25 (56%), and mild reduction in 3/25 (12%) patients. No patients showed progression or were non-responders. Follow-up MRI revealed a lesion size reduction in all patients for which a follow-up MRI was available and complete or partial reduced contrast uptake in 8/10 (80%) patients. Prolonged pain and swelling were observed after 4/41 (9.8%) of BEST sessions. There were no major complications following the treatment of superficial SFVMs, especially no nerve injury. Skin discoloration was observed in 9/25 (36%) of patients while all patients already reported partially fading during follow-up. All complications were temporary only and subsided at follow-up. Discussion: BEST is safe and effective for treating slow-flow vascular malformations of the head and neck region with an acceptable risk- and complication profile.